Natalizumab

Therapeutic indications

Natalizumab is indicated for:

Relapsing remitting multiple sclerosis

Population group: only adults (18 - 65 years old)

Natalizumab is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:

Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT).

Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300 mg once every 4 weeks

Contraindications

Natalizumab is contraindicated in the following cases:

Progressive multifocal leukoencephalopathy (PML)

Progressive multifocal leukoencephalopathy

Increased risk for infections, immunocompromised patients, immunosuppressive therapy

at least one of

Potential for infection
Immunodeficiency
Immunosuppressants

Malignancies except cutaneous basal cell carcinoma

Malignant tumour and additionally not Basal cell carcinoma of skin

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.